Under the terms of the agreement, Hikma will have the exclusive rights to register, distribute and market Zevtera in the Middle East and North America.
Hikma Pharmaceuticals announced that it has entered into an exclusive licensing, supply, and distribution agreement with biopharmaceutical company Basilea Pharmaceutica International for its new generation cephalosporin Zevtera (ceftobiprole medocaril). Zevtera, a new intravenous antibiotic developed for the treatment of pneumonia, has received approvals in 13 European countries and Canada. The antibiotic has been launched in Germany, France, Italy, the United Kingdom.
Under the terms of the agreement, Hikma will have the exclusive rights to register, distribute and market Zevtera in the Middle East and North America.
